🚀 VC round data is live in beta, check it out!
BioAtla Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioAtla and similar public comparables like Acurx Pharmaceuticals, Gelteq, ODI Pharma, Chosa Oncology and more.
BioAtla Overview
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Founded
2007
HQ
Employees
61
Website
Sectors
Financials (FY)
EV
$6M
BioAtla Financials
BioAtla reported last fiscal year revenue of $2M and negative EBITDA of ($59M).
In the same fiscal year, BioAtla generated ($59M) in EBITDA losses and had net loss of ($60M).
Revenue (LTM)
BioAtla P&L
In the most recent fiscal year, BioAtla reported revenue of $2M and EBITDA of ($59M).
BioAtla expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2947%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2965%) | XXX | XXX | XXX |
| Net Profit | ($60M) | XXX | ($60M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2980%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioAtla Stock Performance
BioAtla has current market cap of $7M, and enterprise value of $6M.
Market Cap Evolution
BioAtla's stock price is $4.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $7M | 0.0% | XXX | XXX | XXX | $-35.97 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioAtla Valuation Multiples
BioAtla trades at 3.2x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
BioAtla Financial Valuation Multiples
As of April 12, 2026, BioAtla has market cap of $7M and EV of $6M.
Equity research analysts estimate BioAtla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioAtla has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioAtla Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioAtla Margins & Growth Rates
BioAtla's revenue in the last fiscal year declined by (82%).
BioAtla's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
BioAtla Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (82%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2947%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 887% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2179% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3065% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioAtla Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| ODI Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Quince Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioAtla M&A Activity
BioAtla acquired XXX companies to date.
Last acquisition by BioAtla was on XXXXXXXX, XXXXX. BioAtla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioAtla
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioAtla Investment Activity
BioAtla invested in XXX companies to date.
BioAtla made its latest investment on XXXXXXXX, XXXXX. BioAtla invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioAtla
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioAtla
| When was BioAtla founded? | BioAtla was founded in 2007. |
| Where is BioAtla headquartered? | BioAtla is headquartered in United States. |
| How many employees does BioAtla have? | As of today, BioAtla has over 61 employees. |
| Who is the CEO of BioAtla? | BioAtla's CEO is Jay M. Short. |
| Is BioAtla publicly listed? | Yes, BioAtla is a public company listed on Nasdaq. |
| What is the stock symbol of BioAtla? | BioAtla trades under BCAB ticker. |
| When did BioAtla go public? | BioAtla went public in 2020. |
| Who are competitors of BioAtla? | BioAtla main competitors are Acurx Pharmaceuticals, Gelteq, ODI Pharma, Chosa Oncology. |
| What is the current market cap of BioAtla? | BioAtla's current market cap is $7M. |
| What is the current revenue of BioAtla? | BioAtla's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of BioAtla? | Current revenue multiple of BioAtla is 3.2x. |
| Is BioAtla profitable? | No, BioAtla is not profitable. |
| What is the current net income of BioAtla? | BioAtla's last 12 months net income is ($60M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.